TY - JOUR
T1 - Dynamic alterations of circulating lymphocytes during the trajectory of Hantaan virus-induced hemorrhagic fever with renal syndrome
AU - Su, Lin
AU - Liu, Shuangjuan
AU - Shi, Lei
AU - Cheng, Yuan
AU - Gao, Juanjuan
AU - Guo, Ruirui
AU - He, Yinli
AU - Zhang, Linpei
AU - Chen, Tianyan
AU - Hu, Jinsong
AU - Li, Xiaojiao
AU - Wang, Yawen
N1 - Publisher Copyright:
Copyright © 2025 Su, Liu, Shi, Cheng, Gao, Guo, He, Zhang, Chen, Hu, Li and Wang.
PY - 2025
Y1 - 2025
N2 - Introduction: Hemorrhagic fever with renal syndrome (HFRS) is a zoonotic disease with high mortality. Almost 90% of global cases of HFRS are induced by Hantaan virus (HTNV) infection. Although lymphocyte dysfunction is a critical factor in HFRS progression, the specific immune dynamics of HTNV remain unexplored, and current analyses predominantly depend on single-time point sampling. Therefore, comprehensive longitudinal studies are needed to characterize circulating lymphocyte dynamics during HTNV-induced HFRS progression. Methods: In this study, we conducted a flow cytometric analysis of circulating lymphocytes in 39 patients with HTNV-induced HFRS across different clinical phases. The analysis encompassed conventional T cells, unconventional T cells, B cells, NK cells and their respective repertoires. Results and Discussion: Here, we revealed phase-specific immune patterns: CD8+ T, CD8+ Tems, and activated CD8+ T, MAIT and NKT cells peaked during febrile/oliguric phases before declining in polyuria/recovery, while CD4+ T and MAIT cells showed inverse fluctuation patterns. Higher frequencies of CD8+ Tem, B, and CD56dim NK cells during the febrile phase correlated with severe disease, enabling early risk stratification. Lower CD4+ Tcm levels in the oliguric phase marked progression to severe HFRS, indicating potential therapeutic strategies aimed at enhancing CD4+ Tcm generation or inhibiting effector differentiation. Additionally, CD38 and CD161 expression predicted specific lymphocyte subset dynamics, offering novel biomarkers for immunomodulatory strategies. Our study thus provides the first comprehensive atlas of lymphocyte evolution in HTNV-induced HFRS, connecting immune dysregulation with clinical outcomes.
AB - Introduction: Hemorrhagic fever with renal syndrome (HFRS) is a zoonotic disease with high mortality. Almost 90% of global cases of HFRS are induced by Hantaan virus (HTNV) infection. Although lymphocyte dysfunction is a critical factor in HFRS progression, the specific immune dynamics of HTNV remain unexplored, and current analyses predominantly depend on single-time point sampling. Therefore, comprehensive longitudinal studies are needed to characterize circulating lymphocyte dynamics during HTNV-induced HFRS progression. Methods: In this study, we conducted a flow cytometric analysis of circulating lymphocytes in 39 patients with HTNV-induced HFRS across different clinical phases. The analysis encompassed conventional T cells, unconventional T cells, B cells, NK cells and their respective repertoires. Results and Discussion: Here, we revealed phase-specific immune patterns: CD8+ T, CD8+ Tems, and activated CD8+ T, MAIT and NKT cells peaked during febrile/oliguric phases before declining in polyuria/recovery, while CD4+ T and MAIT cells showed inverse fluctuation patterns. Higher frequencies of CD8+ Tem, B, and CD56dim NK cells during the febrile phase correlated with severe disease, enabling early risk stratification. Lower CD4+ Tcm levels in the oliguric phase marked progression to severe HFRS, indicating potential therapeutic strategies aimed at enhancing CD4+ Tcm generation or inhibiting effector differentiation. Additionally, CD38 and CD161 expression predicted specific lymphocyte subset dynamics, offering novel biomarkers for immunomodulatory strategies. Our study thus provides the first comprehensive atlas of lymphocyte evolution in HTNV-induced HFRS, connecting immune dysregulation with clinical outcomes.
KW - HFRS
KW - HTNV
KW - biomarkers
KW - dynamic alterations
KW - lymphocyte subsets
UR - https://www.scopus.com/pages/publications/105007977524
U2 - 10.3389/fimmu.2025.1567306
DO - 10.3389/fimmu.2025.1567306
M3 - 文章
C2 - 40510360
AN - SCOPUS:105007977524
SN - 1664-3224
VL - 16
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1567306
ER -